Features and Benefits

Fresofos is a sterile powder for solution for intravenous infusion that contains fosfomycin sodium. Fosfomycin has a broad spectrum of activity against a wide range of Gram-positive and Gram-negative bacteria. It shows excellent bactericidal activity against many Gram-negative bacteria such as Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter spp., Citrobacter spp., Serratia marcescens, Neisseria meningitidis, Shigella spp. and Salmonella typhi, and Gram-positive cocci such as methicillin sensitive Staphylococcus aureus (MSSA), cephalosporin and penicillin-resistant Streptococcus pneumoniae, methicillin resistant Staphylococcus aureus (MRSA), and Enterococcus spp., even in vancomycin resistant strains.



Fresofos is available as 4gm vial.


The daily dose of Fresofos is determined based on the indication, severity and site of infection, susceptibility of pathogens to fosfomycin and estimated creatinine clearance. In children, it is also determined by age and body weight.

Adults and adolescents > 12 years of age (>40 kg):

The general dosage guidelines for adults with estimated creatinine clearance >80 ml/min are as follows:


Daily dose

Acute osteomyelitis

12-24 ga in 2-3 divided doses

Complicated urinary tract infection

12-16 gin 2-3 divided doses

Nosocomial lower respiratory tract infection

12-24 gin 2-3 divided doses

Bacterial meningitis

16-24 gin 3-4 divided doses


Individual doses must not exceed 8 g.

aThe high-dose regimen in 3 divided doses should be used in severe infections expected or known to be caused by less susceptible bacteria.
bThere are limited safety data in particular for doses in excess of 16 g/day.

Special caution is advised when such doses are prescribed.

Product Information

Each vial contains:

Fosfomycin sodium BP

Eq. to Fosfomycin 4 g